Sedation in TBI Patients by Peluso, Lorenzo et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter
Sedation in TBI Patients
Lorenzo Peluso, Berta Monleon Lopez and Rafael Badenes
Abstract
Sedation is an important topic in neurocritical patients. When compared with
general intensive care unit and traumatic brain-injured patients, sedation has its
therapeutic indications, such as management of intracranial pressure, treatment of
status epilepticus, sedation for targeted temperature management patients and
paroxysmal sympathetic activity. Nowadays, the assessment of sedation is done by
neurological evaluation and new monitors based on electroencephalography signals
that help the physician titrate the sedative agents. Therefore, the aim of this
chapter is to discuss the main pharmacological properties of sedatives and analge-
sics, their proper indications related to pathophysiological issues and their titrations
based on the abovementioned new technologies.
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1. Introduction
Traumatic brain injury is an acquired brain injury which occurs after a sudden
trauma.
TBI is a major socioeconomic problem. It is an important cause of death and hospital
admissions worldwide. The epidemiology in Europe is not well known, and more
rigorous epidemiological studies are needed to fully quantify the effect of TBI society.
There are primary and secondary injuries. The primary injury is the trauma
suffered by the patient itself, while the secondary injuries develop afterwards due to
hypoxia, alterations in cerebral hemodynamic and metabolism and disruption of the
blood brain barrier. Our aim is to avoid the secondary insults. Examples which can
lead to worsen primary injury are convulsions, fever or intracranial hypertension.
TBI can be divided into different categories based on clinical examination or CT
imaging. The most widely used is the Glasgow Coma Scale (GCS) based on neuro-
logical examination. Three categories can be found: mild, moderate, and severe.
Other neurological scales used are based on time of loss of consciousness (LOC)
(Tables 1 and 2) [1–3].
Many patients being admitted to the ICU are already under sedation due to
neurological reasons. Nowadays, sedative agents are used either as a tool to apply
other therapies (such as hypothermia) or as a treatment itself, for example, barbi-
turate coma for refractory hypertension.
Sedation and analgesia are practices that, all clinicians who provide care to patients
affected by traumatic brain injury, have to face daily. These patients are usually
excluded from randomized clinical trials, so the level of evidence in this setting is still
low. The aims of sedation and analgesia can be divided into two main categories.
Firstly, general objectives are to ensure the patients’ comfort, reduction of pain
and agitation, improvement of patient-ventilator synchrony and facilitation of the
nursing caring.
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Specific objectives focused on “neurotreatment” are the reduction of intracranial
pressure (ICP), the management of status epilepticus (SE), the control of targeted
temperature management (TTM), the management of paroxysmal sympathetic
activity and the decrease of cerebral oxygen consumption [1, 2].
A variety of studies show the positive outcomes of an adequate sedation and
analgesia in the general critical care patient as, for example, reduce time on the
ventilator and decrease the length of stay in ICU and prevention of neurologic
deterioration, amongst others.
The best way to assess these patients is with the physical examination, allowing a
clinical monitoring and timely detection of warning neurological signs; thus, the
removal of the sedative agent is required. However, this can lead to a cerebral and
hemodynamic derangement when sedation is abruptly stopped [3]. Cerebral
hypoperfusion and raised ICP might result in an imbalance of energy supply and
demand, especially for the injured brain and, therefore, aggravate the risk for
metabolic distress and brain tissue hypoxia. It might lead to significant ICP eleva-
tion and cerebral perfusion pressure (CPP) reduction, but it has been shown that, in
patients with a stable ICP and CPP readings, the wake-up tests remain the gold
standard for clinical monitoring and detection of neurological changes [4].
Available drugs used for sedation are analgesics and sedatives. Evidence shows
that combining them both in order to achieve the optimal level of sedation leads to a
reduction in the appearance of adverse effects.
Parameter Response Score
Best eye-opening response -Spontaneously 4
-To verbal request 3
-To pain 2
-No response 1
Best verbal response -Oriented and conversational 5
-Disoriented and conversational 4
-Inappropriate words 3
-Incomprehensible sounds 2
-No response 1
Best motor response -Obesity request 6
-Appropriate withdrawal 5
-Flexion withdrawal 4
-Flexion decorticate 3
-Extension 2
-No response 1
Table 1.
GCS classification
GCS LOC
Mild 14–15 0–30 min
Moderate 9–13 30 min–24 h
Severe 3–8 >24 h
Table 2.
TBI classification: GCS and LOC time.
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Control patients’ level of sedation plays an important role in what recently has
been described as the “ABCDE bundle.” An evidence-based clinical approach
improves patients’ outcome and recovery [5] such as duration of mechanical venti-
lation, brain dysfunction (i.e., delirium and coma), physical restraints, ICU
readmission rates, and discharge disposition of ICU survivors.
In this chapter we will go over the basis of sedation in TBI patients, as well as the
pharmacology of the different drugs used and the main indication for such patients.
2. Pharmacology of sedatives and analgesics
The ideal sedative drug for a neurocritical patient should have different proper-
ties. It should have a rapid onset and recovery for a prompt neurologic evaluation, a
predictable clearance independent of end-organ failure to avoid the accumulation of
the drug, and it should be easily titrated. It has to reduce ICP by reducing cerebral
blood flow (CBF) or cerebral vasoconstriction, however maintaining the coupling
between cerebral blood flow and cerebral metabolic rate of oxygen consumption
(CMRO2). Cerebral autoregulation should be preserved as well as normal vascular
reactivity to changes in PaCO2. Finally, the hemodynamic depression should be
minimal to avoid deleterious effects on brain circulation.
2.1 Propofol
Propofol is a central nervous system depressant which directly activates GABA
receptors and inhibits the NMDA receptor modulating calcium influx through slow
calcium ion channels. It has a rapid onset (1–2 min) and a dose-related hypnotic effect.
Its rapid onset is due to its high lipophilic property and a large volume of distribution,
leading to a rapid recovery too (10–15 min). These characteristics made propofol one
of the best alternatives for sedation in neurocritical patients allowing us to do wake-up
test daily for neurologic evaluation. Some studies show that in patients requiring >48 h
of mechanical ventilation [6], sedation with propofol results in significantly fewer
ventilator days than intermittent lorazepam when sedatives are interrupted daily.
Propofol has no active metabolites and does not produce significant drug interactions.
It reduces ICP, CMRO2, CBF and cerebral electrical activity. CO2 vascular reactivity
and cerebral autoregulation are also preserved. On the other hand, it has no analgesic
effect, and it raises tolerance and tachyphylaxis. Side effects of propofol are dose-
dependent hypotension which can decrease cerebral perfusion pressure even if it
induces a decrease in ICP [6] and dose-dependent respiratory depression. Thus, inva-
sive blood pressure and maybe cardiac output monitoring may be necessary.
Hypertriglyceridemia may appear after high-rate infusions; clinicians should
also be aware of the propofol infusion syndrome (PRIS) to detect it as soon as
possible. PRIS manifests as metabolic acidosis, hyperkalemia, rhabdomyolysis,
hypoxia and progressive myocardial failure [7–9].
2.2 Benzodiazepines
Benzodiazepines such asmidazolam, lorazepam and diazepamare sedativeswidely
used in the ICU. They have anxiolytic, sedative and hypnotic properties. Midazolam is
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a GABA receptor agonist. Systemic effects of these drugs are anxiolysis, sedation,
muscle relaxation, anterograde amnesia, respiratory depression and anticonvulsant
activity. It decreases CMRO2 and CBF and has a slight effect on lowering ICP too. As
with propofol, vascular reactivity to CO2 and cerebral autoregulation is preserved.
Midazolam produces amnesia and has a rapid onset of action, and it produces less
hemodynamic instability than propofol. However, they also produce tolerance and
tachyphylaxis. Their metabolism is impaired when hepatic failure because of its oxi-
dation via CYP450 enzyme system producing activemetabolites excreted in the urine,
leading to accumulation in renal dysfunction. It can prolong duration of mechanical
ventilation, and the appearance of delirium in the ICU patients is increased. A contin-
uous infusion of midazolam for more than 24 h will lose the rapid recovery properties
due to the accumulation of active metabolites. Therefore, it is recommended only for
short-term infusions. The Society of Critical Care Medicine consensus guidelines state
that midazolam should be used only for short-term (<48 h) therapy [10]. High doses
of benzodiazepines can cause respiratory depression and apnea, leading to an increase
in ICP caused by hypercapnia. Benzodiazepines’ reverser is flumazenil.
2.3 Opioids
Morphine, fentanyl and remifentanil are the most frequently used opioids in the
ICU [11]. These drugs stimulate mu, kappa and delta receptors, distributed all along
the central nervous system (CNS). They have a fast onset when given intravenous
(iv), and they are more easily titrated. Morphine and meperidine are not the ideal
sedative agent for ICU because their active metabolite can precipitate seizures [12].
Moreover, morphine has a long-lasting effect. Fentanyl with its high lipid solubility
has a very rapid onset and a short duration of action when given as a bolus; how-
ever, the pharmacokinetics change when administered in perfusion. It may increase
ICP and decrease CPP (decrease in MAP) transiently after a bolus. Remifentanil is
more powerful than morphine, and it is metabolized directly in the plasma by
nonspecific esterases, thus avoiding drug accumulation. Due to its very short dura-
tion of action, it requires a continuous perfusion [13–17]. This makes this drug very
suitable for neurocritical patients because it facilitates frequent awakening for the
neurologic evaluation [18]. Remifentanil is eliminated by the kidneys, and it does
not have to be adjusted if kidney failure. On the other side, as they act as respiratory
depressants, they may cause hypercapnia with consequent increase in ICP. They can
induce histamine release, causing urticaria and flushing, somnolence respiratory
depression, chest wall and other muscle rigidity, dysphoria or hallucinations, nausea
and vomiting, gastrointestinal dysmotility and vasodilation with hypotension. The
reverser is naloxone, which should be given slowly and be titrated.
In order to reduce and minimize the use of opioids, it is possible to add other
categories of analgesics as gabapentin and/or acetaminophen [19].
2.4 Dexmedetomidine
Dexmedetomidine is an alpha-2 agonist which has been recently introduced into
clinical practice. It has sedative, analgesic and anxiolytic properties, and it is widely
starting to spread through the neurointensive care unit (NICU). It has a short-acting
effect, and it does not accumulate, thus being very appropriate for frequently wake-
up test for neurological evaluation. The respiratory depression is minimal, and it has
been reported that it may reduce the incidence and severity of delirium. On the
other side, it is a very expensive drug, and there have been reported cases of dose-
dependent bradycardia, hypotension, arrhythmias and hyperglycemia. Deep seda-
tion is not possible with this drug [20–24]. The pharmacokinetics is influenced by
liver rather than renal function. Dexmedetomidine is metabolized in the liver by
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CYP450 enzyme system, and there are no active or toxic metabolites. Sedation with
volunteers showed a decrease in regional and global cerebral blood flow, but the
ratio with CMRO2 and flow metabolism coupling is maintained [25]. The
neuroprotective effect in animal studies has also been studied, and they showed a
preconditioning effect and attenuation of ischemia-reperfusion injury [26].
2.5 Barbiturates
Nowadays, these drugs are used only for a specific goal. They are a GABA
receptor agonist leading to a decrease in ICP and CBF that is proportional to the
decrease in CMRO2 (up to 60%) during burst suppression. Barbiturates have been
associated with a high incidence of systemic complications, such as hemodynamic
instability and immune suppression with an increased risk of infections, such as
pneumonia. Indication for barbiturates is limited to refractory intracranial hyper-
tension and refractory status epilepticus [27]. They accumulate in the tissues after
long-term infusions leading to slow recovery from sedation.
2.6 Ketamine
Ketamine is an NMDA receptor antagonist with a relatively good hemodynamic
stability. It has a fast onset and a short action. Sedation, analgesia and anesthesia can
be induced with this drug, and it does not depress the respiratory system. Potential
side effects of ketamine are increase of CMRO2, CBF and ICP (due to an increase in
cerebral blood volume). However, some reports have shown to decrease CBF and
ICP in head trauma patients sedated using both ketamine and propofol or with a
PaCO2 maintained constant [28], and in an experimental setting ketamine even had
neuroprotective properties [29]. Main advantages of using ketamine are the hemo-
dynamic stability as well as CPP and the opportunity to reduce the excessive use of
some sedative drugs as it reinforces them.
In a recent study, the use of ketamine was associated with a lower incidence of
cortical spreading depolarization (CSD) when compared with propofol, midazolam
and opioids [30].
2.7 Inhalation sedatives
Inhalative sedation in the ICU is starting to spread all over Europe and has been
recommended as an alternative in a German consensus guideline [31]. However, it
has historically been considered unsafe in the NICU around the world. Isoflurane,
sevoflurane, and desflurane have shown some benefits compared with intravenous
sedation. They have a low metabolism and, due to their low solubility, are elimi-
nated quickly and offer shorter and more predictable wake-up times than intrave-
nous agents. They give also a better hemodynamic stability. Some volatile
anesthetics abolish cerebral autoregulation at high doses; it has been reported that
with sevoflurane at MAC 1.0, the autoregulation of cerebral blood flow remained
intact, but it was impaired at MAC 2.0. They have also a dose-dependent
neuroprotective effect; sevoflurane at MAC 0.5 does not have this effect [32].
In a prospective study, it was seen that sufficient sedation levels without clini-
cally relevant ICP increases were achieved in 68% of the patients. However, MAP
had to be maintained actively to preserve the CPP. Therefore, it was concluded that
the neuroprotective effect did not outweigh the risk of adverse events, and sedation
with this agent should not be carry out in these patients [33].
A summary table can be found at the end of the chapter.
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Mechanism
of action
Rapid
onset
Fast
recovery
Metabolism IV Bolus
dose
Continuous IV
infusion
ICP
reduction
CBF
reduction
CMRO2
reduction
Map
reduction
Main advantages Main
disadvantages
Adverse effects
Propofol GABA R
agonist
+++ +++ Hepatic 1.5–2.5 mg/kg 5–200 mg/kg/min Clearance
independent of renal
or hepatic function.
Rapid onset and fast
recovery
No analgesia.
Tolerance and
tachyphylaxis.
Increases
triglycerides.
PRIS. Hypotension
Midazolam GABA R
agonist
+++ ++ Hepatic 0.02–
0.08 mg/kg
0.04–0.3 mg/kg/h Amnesia. Rapid
onset
Tolerance.
Tachyphylaxis.
Accumulates in
renal dysfunction.
Active metabolites
Hypotension. Apnea.
Delirium
Morphine MU-R agonist + + Hepatic 0.8–10 mg/h Max 80 mg/h Less peripheric
accumulation than
fentanyl. Analgesia
Hypotension Apnea. Hypotension.
Pruritus. Nausea. Active
metabolite can produce
seizures. Muscle rigidity
Fentanyl MU-R agonist +++ ++ Hepatic 25–125 mg 10–100 mg/h More potent
analgesic than
morphine
Accumulation with
hepatic impairment.
Apnea
Pruritus. Nausea.
Muscle rigidity.
Remifentanil MU-R agonist +++ +++ Plasmatic
esterases
0.05–0.25 mg/kg/min 500 more potent
than morphine
Hyperalgesia after
infusion. CV
depressant.
Dexdor ALPHA 2
agonist
++ ++ Hepatic Not
recommended
0.2–1.4 mg/kg/h Sedative, anxiolytic,
analgesic. Minimal
respiratory
depression. Reduces
delirium
Limited experience
in ABI.
Arrhythmias.
Hypotension.
Bradicardia.
Thiopental GABA R
agonist
+++ + Hepatic 2–5 mg/kg 1–5 mg/kg/h Second-line
treatment for
refractory
intracraneal
hypertension
Accumulates in
peripheral tissue.
Adjust dose in renal
failure.
HD instability.
Immunosuppression.
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Mechanism
of action
Rapid
onset
Fast
recovery
Metabolism IV Bolus
dose
Continuous IV
infusion
ICP
reduction
CBF
reduction
CMRO2
reduction
Map
reduction
Main advantages Main
disadvantages
Adverse effects
Ketamine NMDA R
agonist
+++ +++ Liver 1–4 mg/kg (0.5–2 mg/kg) Sedation, anesthesia,
analgesia. No
respiratory
depression. HD
stability.
Increases secretions. Hallucinations.
Nystagmus. Increases
IOP, IAP
Sevorane Not clear.
GABA R
agonist +
glutamate
receptor
agonist
+++ ++ 5% Hepatic.
95%
inhalatory
pathway
2% MAC 0.5–3% of sevorane in May
increase
after
increase
in CBF
Fast elimination.
Increases CBF in
cerebral ischemia.
Hypotension. MAC
2 autoregulation
impairs.
Toxic metabolite
(compound A).
Malignant hyperthermia
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3. Physiologic effects of sedatives on cerebral blood flow and cerebral
metabolic rate of oxygen consumption
Sedation is one of the pillars in the management of patients with TBI. It is a
treatment itself when used to prevent the secondary insult, and it allows other mea-
sures to be implemented which could not be applied otherwise, such as hypothermia.
The physiologic effects of sedatives are different, and they can be divided into
effects on CBF and CMRO2.
3.1 Effects on cerebral blood flow (CBF)
One of the main goals when treating these patients is to maintain a
sufficient cerebral blood flow. Therefore, our drugs should have little or no effect
on this matter.
The effects of intravenous sedatives on CBF have been investigated for
diazepam, midazolam and propofol. All these iv agents cause a dose-dependent
decrease in CMRO2 and CBF. CBF reduction is an adaptative phenomenon to
minimize brain metabolism. They usually have a systemic effect decreasing mean
arterial pressure (MAP), inducing myocardial depression and peripheral vasodila-
tion. Therefore, in patients with impaired autoregulation, such as those with TBI,
decreasing the MAP can lead to a critical lowering in cerebral perfusion pressure
and oxygen delivery to the brain. This can lead or worsen the secondary brain insult
(ischemia/hypoxia) [34, 35]. If autoregulation is intact, this reduction on MAP
will produce reflex cerebral vasodilation and may lead to an increase in intracranial
pressure [36]. The hemodynamic effects are usually dose dependent, so it is
important to assess the preload status of the patient in order to predict the
hemodynamic response to the sedative agent, particularly in those with previous
cardiac dysfunction.
3.2 Effects on the cerebral metabolic rate of oxygen consumption (CMRO2)
The CMRO2 and CBF are nicely connected. In TBI patients, our target is to
maintain an adequate oxygen availability and energy balance; thus, we aim to
increase oxygen delivery by optimizing cerebral and systemic hemodynamic, as
well as attenuating metabolic demands [2, 37, 38].
Patients in coma or suffering from secondary brain insults have their cerebral
metabolism decreased globally by one-third to one-half of normal levels.
Sedative agents act by reducing CMRO2, improving cerebral tolerance to ische-
mia and limiting the supply/demand mismatch in conditions of impaired
autoregulation [34, 35]. Beyond the level of isoelectric EEG, no further suppression
of cerebral oxygen consumption can take place; a minimal oxygen consumption is,
indeed, due to cells’ homeostasis.
4. Neurological indications for sedation
Continuous infusion of sedative agents is contemplated during the first 48 h, in
order to prevent secondary brain injury by decreasing oxygen consumption, as well
as to reduce pain, anxiety and agitation to tolerate mechanical ventilation.
Apart from the general indications due to patient’s agitation and pain
control, there are specific situations in these patients that require sedation
as therapy.
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4.1 Control of intracranial pressure (ICP)
The effect of sedatives on ICP is due mainly to reduction in CMRO2 that leads to
a decrease in cerebral blood flow. This effect can be seen as a decrease in cerebral
blood volume that leads to a decrease in ICP. As well, sedation reduces pain and
agitation and improves the tolerance to the endotracheal tube. These effects lead to
a decrease of sympathetic activity with a reduction of arterial pressure and less
ventilation asynchronies leading to a decrease of jugular venous resistance and a
better venous outflow.
Sedation is a first-line therapy that should be integrated with other specific
interventions as hyperventilation, osmotic agents and head-of-bed elevation. Bolus
of opioids needs caution for the transient decrease in mean arterial pressure and
increase in ICP due to autoregulatory cerebral vasodilation [36]. When compared
with opioids, propofol showed an association with a lower ICP and less ICP treat-
ments in patients with severe traumatic brain injury (TBI) [6].
4.2 Targeted temperature management (TTM)
The effects of hypothermia on the brain are multiple. First, the cerebral meta-
bolic rate decreases leading to a decrease in CBF and, consequently, a reduction of
cerebral volume. Moreover, cooling procedures suppress many of the pathways that
lead to cell death, including apoptotic mechanisms (programmed cell death).
Sedation is recommended during TTM to prevent shivering, to reduce the stress
response and to allow the patient-ventilator synchrony. To avoid shivering a lot of
drugs are available, but they could engender side effects. One of the most used
drugs is propofol that has a dose-dependent antishivering effect.
An excess in sedation can lead to an increase of mechanical ventilation time and
a delay in neurological response [39].
4.3 Treatment of status epilepticus (SE)
Status epilepticus is a quite common neurologic condition with an overall inci-
dence of 41–61 cases per 100,000 patients/year [40].
The emergency therapy consists in benzodiazepines for the emergency,
followed by one or more anti-epileptic drugs (AED). When both categories fail, it is
necessary to begin a deep sedation with anesthetic agents for at least 24 h of
effectiveness [41].
Different studies showed and reported the effectiveness of propofol or
midazolam as therapy for refractory SE.
The traditional barbiturate (phenobarbital), due to its side effects, is being
replaced by the newest propofol and midazolam.
4.4 Paroxysmal sympathetic activity
This syndrome has been recognized in a subgroup of survivors of severe
acquired brain injury, characterized by simultaneous, paroxysmal transient
increases in sympathetic (elevated heart rate, blood pressure, respiratory rate, tem-
perature, sweating) and motor (posturing) activity. This syndrome has been
observed for the last 60 years. It affects 8–10% of patients suffering from acute
brain injury, and it is associated with greater morbidity, higher healthcare costs,
longer hospitalization and poorer outcomes. However, it is a potentially treatable
contributor to secondary brain injury. In patients surviving traumatic brain injury,
it has been associated with severe anoxia, subarachnoid and intracerebral
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hemorrhage and hydrocephalus. There are many theories dealing with the patho-
physiology of this entity. Disconnection of the inhibitory efferent pathways
(malfunctioning pathways) from cortical areas of the brain is one of the possible
theories. It is also thought that alterations in the excitatory nucleus of the brainstem
can cause this syndrome; excitatory centers are then upregulated, increasing sym-
pathetic activity. There is no accepted treatment for this entity. The objective is to
mitigate signs and symptoms to avoid the adverse effects such as dehydration,
muscle wasting or delayed recovery. Dopaminergic agents have shown to decrease
body temperature and sweating. Alpha agonists can decrease heart rate and blood
pressure. When medication fails, the use of hyperbaric oxygen therapy (HBOT) to
control autonomic discharges and posturing in the subacute TBI phase has been
reported. In this condition, sedation should be considered to reduce sympathetic
activation [42].
5. Monitoring sedation in the neuro-ICU
Monitoring the depth of sedation is essential in the management of the patient in
the ICU, and it influences their outcomes. Oversedation increases the risk of infec-
tions by delaying weaning from mechanical ventilation and increases length of stay
and, thus, costs. On the other side, undersedation can cause agitation and anxiety of
the patient, increase the risk of self-extubating and develop asynchronies between
the patient and the ventilator. In NICU patients, assessing routine level of sedation
is really important both for the daily wake-up tests that should be done for neuro-
logic evaluation and, in comatose patients, to avoid oversedation.
There are various scales available for ICU patients. The Ramsay Sedation Scale
evaluates consciousness, while the Richmond Agitation-Sedation Scale (RASS)
examines cognition. The Motor Activity Assessment Scale (MAAS) and the
Sedation-Agitation Scale (SAS) monitor sedation and arousal. Both RASS and SAS
are reasonable to use in TBI patients [43]. Moreover, RASS is usually integrated
with a delirium assessment performed with Confusion Assessment Method for the
ICU (CAM-ICU). However, in deeply sedated patients and with muscular blockade,
these scales become useless. EEG monitoring has therefore become a very investi-
gated topic to titrate sedation in these patients. Simplified EEG tools like BIS, based
on Fourier transform, have shown significant correlation with RASS and SAS in ABI
[44]. However, BIS was developed to monitor sedation in the operating room (OR)
setting in patients with no acute brain injury (ABI) due to the possible changes in
EEG because of the brain lesion; it is often used in the ICU setting.
The possible confounders of such method are shivering, temperature fluctua-
tion, increased muscle tone, grimacing and catecholamine levels. To assess the
adequacy of pain relief, it is useful to assess autonomic signs of activation such as
tachycardia, hypertension, ICP increase and diaphoresis.
6. Conclusions
Sedation and analgesia are widely used in NICU and all clinicians who provide
care to neuropatients’ face daily with such practice. The indication for sedation in
NICU could be general or properly neurologic that is considered as a therapy in the
acute brain injury patient. Sedation, indeed, allows a better control of cerebral
hemodynamic and is part of control of intracranial pressure.
The knowledge of basic principles of pharmacology, neurophysiology, and neu-
ropathology remains, therefore, essential to manage such kind of therapy.
10
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Propofol and midazolam seem to be the most used drugs in such patient due to
their security profile; ketamine appears to be interesting for its neuroprotective
role.
To target sedation properly, it is possible to use different approaches; the use of
score (RASS, SAS) in the awake patient remains a good tool that can be integrated
in comatose patient, knowing their limits, with the newest EEG-derived methods.
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